Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53

Ming Fu Chiang, Shu Ting Yeh, Hui Fen Liao, Nan-Shan Chang, Yu Jen Chen

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: Human WWOX gene encoding WW domain-containing oxidoreductase, named WWOX, FOR, or WOX1, has been studied in various types of cancer cells and shown to be a tumor suppressor with pro-apoptotic properties. Mutation or gain-of-function of p53 in glioma cells is associated with resistance to radiation therapy and poor prognosis. In this study, we overexpressed WOX1 to examine the pro-apoptotic activity against human glioblastoma cells harboring mutant p53. Methods: Overexpression of WOX1 in glioblastoma cell lines and apoptosis-related assays were performed. Results: Our results showed that overexpressed WOX1 induced apoptosis of glioblastoma U373MG harboring mutant p53 by causing hypoploidy and DNA fragmentation. However, ectopic WOX1 had no effect with U87MG possessing wild type p53. Unlike temozolomide, WOX1 induced apoptosis of U373MG cells via a mitochondria-independent and caspase-3-independent pathway. Conclusions: Overexpression of WOX1 preferentially inhibited viability and induced apoptosis in human glioblastoma cells expressing mutant p53 via a mechanism independent of the intrinsic apoptotic pathway. Conceivably, the survival of human glioblastoma cells depends upon interactions between the gain-of-function of p53 and WOX1. This suggests that modulation of WOX1 expression may be a novel strategy for treating human glioblastoma cells with mutant p53.

Original languageEnglish
Pages (from-to)433-438
Number of pages6
JournalBiomedicine and Pharmacotherapy
Volume66
Issue number6
DOIs
Publication statusPublished - 2012 Sep 1

Fingerprint

Glioblastoma
Oxidoreductases
Apoptosis
temozolomide
DNA Fragmentation
Human Activities
Glioma
Caspase 3
Neoplasms
Mitochondria
Radiotherapy
Cell Line
Mutation
Survival
Genes

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

@article{59b2ccabc1414294a47dc07ed522a825,
title = "Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53",
abstract = "Purpose: Human WWOX gene encoding WW domain-containing oxidoreductase, named WWOX, FOR, or WOX1, has been studied in various types of cancer cells and shown to be a tumor suppressor with pro-apoptotic properties. Mutation or gain-of-function of p53 in glioma cells is associated with resistance to radiation therapy and poor prognosis. In this study, we overexpressed WOX1 to examine the pro-apoptotic activity against human glioblastoma cells harboring mutant p53. Methods: Overexpression of WOX1 in glioblastoma cell lines and apoptosis-related assays were performed. Results: Our results showed that overexpressed WOX1 induced apoptosis of glioblastoma U373MG harboring mutant p53 by causing hypoploidy and DNA fragmentation. However, ectopic WOX1 had no effect with U87MG possessing wild type p53. Unlike temozolomide, WOX1 induced apoptosis of U373MG cells via a mitochondria-independent and caspase-3-independent pathway. Conclusions: Overexpression of WOX1 preferentially inhibited viability and induced apoptosis in human glioblastoma cells expressing mutant p53 via a mechanism independent of the intrinsic apoptotic pathway. Conceivably, the survival of human glioblastoma cells depends upon interactions between the gain-of-function of p53 and WOX1. This suggests that modulation of WOX1 expression may be a novel strategy for treating human glioblastoma cells with mutant p53.",
author = "Chiang, {Ming Fu} and Yeh, {Shu Ting} and Liao, {Hui Fen} and Nan-Shan Chang and Chen, {Yu Jen}",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.biopha.2012.03.003",
language = "English",
volume = "66",
pages = "433--438",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "6",

}

Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53. / Chiang, Ming Fu; Yeh, Shu Ting; Liao, Hui Fen; Chang, Nan-Shan; Chen, Yu Jen.

In: Biomedicine and Pharmacotherapy, Vol. 66, No. 6, 01.09.2012, p. 433-438.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53

AU - Chiang, Ming Fu

AU - Yeh, Shu Ting

AU - Liao, Hui Fen

AU - Chang, Nan-Shan

AU - Chen, Yu Jen

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Purpose: Human WWOX gene encoding WW domain-containing oxidoreductase, named WWOX, FOR, or WOX1, has been studied in various types of cancer cells and shown to be a tumor suppressor with pro-apoptotic properties. Mutation or gain-of-function of p53 in glioma cells is associated with resistance to radiation therapy and poor prognosis. In this study, we overexpressed WOX1 to examine the pro-apoptotic activity against human glioblastoma cells harboring mutant p53. Methods: Overexpression of WOX1 in glioblastoma cell lines and apoptosis-related assays were performed. Results: Our results showed that overexpressed WOX1 induced apoptosis of glioblastoma U373MG harboring mutant p53 by causing hypoploidy and DNA fragmentation. However, ectopic WOX1 had no effect with U87MG possessing wild type p53. Unlike temozolomide, WOX1 induced apoptosis of U373MG cells via a mitochondria-independent and caspase-3-independent pathway. Conclusions: Overexpression of WOX1 preferentially inhibited viability and induced apoptosis in human glioblastoma cells expressing mutant p53 via a mechanism independent of the intrinsic apoptotic pathway. Conceivably, the survival of human glioblastoma cells depends upon interactions between the gain-of-function of p53 and WOX1. This suggests that modulation of WOX1 expression may be a novel strategy for treating human glioblastoma cells with mutant p53.

AB - Purpose: Human WWOX gene encoding WW domain-containing oxidoreductase, named WWOX, FOR, or WOX1, has been studied in various types of cancer cells and shown to be a tumor suppressor with pro-apoptotic properties. Mutation or gain-of-function of p53 in glioma cells is associated with resistance to radiation therapy and poor prognosis. In this study, we overexpressed WOX1 to examine the pro-apoptotic activity against human glioblastoma cells harboring mutant p53. Methods: Overexpression of WOX1 in glioblastoma cell lines and apoptosis-related assays were performed. Results: Our results showed that overexpressed WOX1 induced apoptosis of glioblastoma U373MG harboring mutant p53 by causing hypoploidy and DNA fragmentation. However, ectopic WOX1 had no effect with U87MG possessing wild type p53. Unlike temozolomide, WOX1 induced apoptosis of U373MG cells via a mitochondria-independent and caspase-3-independent pathway. Conclusions: Overexpression of WOX1 preferentially inhibited viability and induced apoptosis in human glioblastoma cells expressing mutant p53 via a mechanism independent of the intrinsic apoptotic pathway. Conceivably, the survival of human glioblastoma cells depends upon interactions between the gain-of-function of p53 and WOX1. This suggests that modulation of WOX1 expression may be a novel strategy for treating human glioblastoma cells with mutant p53.

UR - http://www.scopus.com/inward/record.url?scp=84866156432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866156432&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2012.03.003

DO - 10.1016/j.biopha.2012.03.003

M3 - Article

C2 - 22898080

AN - SCOPUS:84866156432

VL - 66

SP - 433

EP - 438

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 6

ER -